Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma.

about

The prostaglandin D receptor 2 pathway in asthma: a key player in airway inflammation

P2860

Q58795817-670E17DC-1B60-4DD5-BCEB-7C94AAE6034C

P2860

Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma.

Item

http://www.wikidata.org/entity/Q50636722

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Discovery of Fevipiprant (NVP- ...... onist for Treatment of Asthma.

@en

Discovery of Fevipiprant (NVP- ...... onist for Treatment of Asthma.

@nl

type

Item

label

Discovery of Fevipiprant (NVP- ...... onist for Treatment of Asthma.

@en

Discovery of Fevipiprant (NVP- ...... onist for Treatment of Asthma.

@nl

prefLabel

Discovery of Fevipiprant (NVP- ...... onist for Treatment of Asthma.

@en

Discovery of Fevipiprant (NVP- ...... onist for Treatment of Asthma.

@nl

P1476

Discovery of Fevipiprant (NVP- ...... onist for Treatment of Asthma.

@en

P2093

Bindi Sohal

http://www.w3.org/2001/XMLSchema#string

Brian Cox

http://www.w3.org/2001/XMLSchema#string

Catherine Ritchie

http://www.w3.org/2001/XMLSchema#string

David A Sandham

http://www.w3.org/2001/XMLSchema#string

David Budd

http://www.w3.org/2001/XMLSchema#string

Devnandan Chatterjee

http://www.w3.org/2001/XMLSchema#string

Duncan Shaw

http://www.w3.org/2001/XMLSchema#string

Edward Hall

http://www.w3.org/2001/XMLSchema#string

Elisabeth Willard

http://www.w3.org/2001/XMLSchema#string

Gareth Williams

http://www.w3.org/2001/XMLSchema#string

P2860

Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2

Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs

Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy.

Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers.

The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma.

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.

Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells.

CRTH2 antagonists in the treatment of allergic responses involving TH2 cells, basophils, and eosinophils.

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases.

P304

582-586

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ACSMEDCHEMLETT.7B00157

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28523115

http://www.w3.org/2001/XMLSchema#string

P932

5430394

http://www.w3.org/2001/XMLSchema#string

Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma.

about

P2860

P2860

Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932